Trial reportEuropean heart journal. Cardiovascular Imaging2015
The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study.
Trial report in European heart journal. Cardiovascular Imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01567826 (Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy.), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy. (YELLOW Trial)
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Statin Use and Coronary Artery Calcification: a Systematic Review and Meta-analysis of Observational Studies and Randomized Controlled Trials.Current atherosclerosis reports · 2023Pooled it
- Achieved LDL-C levels <55 mg/dL and cardiac events in patients and lesions harbouring lipid-rich plaque phenotypes.European heart journal. Cardiovascular Imaging · 2026Article
- Novel imaging modalities for the identification of vulnerable plaques.Frontiers in cardiovascular medicine · 2024Review
- Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging.American journal of preventive cardiology · 2022Review
- The impact of lipid-lowering medications on coronary artery plaque characteristics.American journal of preventive cardiology · 2021Article
- Review
- Near-Infrared Spectroscopy Intravascular Ultrasound Imaging: State of the Art.Frontiers in cardiovascular medicine · 2020Review
- Associations of ABCG1-mediated cholesterol efflux capacity with coronary artery lipid content assessed by near-infrared spectroscopy.Cardiovascular diagnosis and therapy · 2019Article
- Plaque characteristics and slow flow during percutaneous coronary intervention of irregular protrusion by optical coherence tomography.Heart and vessels · 2019Article
- The role of near-infrared spectroscopy in the detection of vulnerable atherosclerotic plaques.Archives of medical science : AMS · 2016Article
- A Review of Intravascular Ultrasound-based Multimodal Intravascular Imaging: The Synergistic Approach to Characterizing Vulnerable Plaques.Ultrasonic imaging · 2016Review
- Review
- Protein kinase C regulation of GABAA receptors.Cellular and molecular life sciences : CMLS · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aimsTo evaluate the relationship between lipid content and plaque morphometry as well as the process of lesion progression and regression in patients with significant coronary artery disease. METHODS AND
resultsThe present study, using data from the YELLOW trial, was conducted in patients having significant coronary lesions (fractional flow reserve <0.8) who underwent serial intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) at baseline and after 7 weeks. For each coronary plaque (≥50% plaque burden that was ≥5 mm in length), we evaluated plaque characteristics and the extent of lipid-rich plaque [LRP, defined as the 4 mm long segment with the maximum lipid-core burden index (maxLCBI4 mm)] on NIRS. Among 66 patients (age 63.0 ± 10.1 years; 82% statin use at baseline), 94 plaques were identified. The extent of LRP at baseline was positively correlated with IVUS plaque burden (r = 0.317, P = 0.002). A large LRP (maxLCBI4 mm ≥500) was present only in plaques with a large plaque burden (≥70%). Multivariate analysis demonstrated that plaque burden was the best predictor of the extent of LRP (P < 0.001). In lesions with a large plaque burden and a large amount of LRP at baseline, a reduction in LRP was seen in all lesions in patients receiving intensive statin therapy (P = 0.004) without a significant change in plaque burden.
conclusionsCoronary lesions containing a large amount of LRP also had a large plaque burden. Short-term regression of LRP (without a change in plaque burden) was observed mainly in plaques with a large plaque burden and a large amount of LRP at baseline. CLINICAL
trial registrationhttp://www.clinicaltrials.gov. Unique identifier: NCT01567826.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.